Jasper Therapeutics said an investigation has traced unexpectedly weak results in two multi-dose cohorts of its briquilimab chronic hives trial and in an asthma study to a single manufacturing lot of the drug. In the BEACON Phase 1b/2a study, 8 of 9 patients (89%) in the 240 mg and 360 mg single-dose chronic-spontaneous-urticaria cohorts achieved complete responses, but data from regimens that relied on the compromised lot could not be interpreted. The same material was used in the ETESIAN asthma trial, which the company is now terminating. No Grade 3 or higher treatment-related adverse events were reported. To preserve cash while it repeats affected cohorts and prepares a Phase 2b hives study, Jasper will halt development in asthma and severe combined immunodeficiency, cut its workforce by roughly 50%, and see its chief medical officer depart. The company plans to enroll 10–12 additional CSU patients with validated drug supply and expects new data in the fourth quarter of 2025. Jasper shares fell about 65% in early trading on 7 July after the quality-control lapse became public.